PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30801659-9	2019	CONCLUSIONS AND IMPLICATIONS: Tolvaptan inhibited AngII-stimulated aldosterone production via a V2 receptor-independent pathway, which can counteract or even surpass its potential activating effect of diuresis-induced aldosterone secretion in certain aldosterone-mediated pathological conditions.	Tolvaptan	30-39	angiotensinogen	Homo sapiens	50-55	
30801659-1	2019	BACKGROUND AND PURPOSE: We investigated the inhibitory effect and associated molecular mechanisms of tolvaptan on angiotensin II (AngII)-induced aldosterone production in vitro and in vivo.	Tolvaptan	101-110	angiotensinogen	Homo sapiens	114-128	
30801659-1	2019	BACKGROUND AND PURPOSE: We investigated the inhibitory effect and associated molecular mechanisms of tolvaptan on angiotensin II (AngII)-induced aldosterone production in vitro and in vivo.	Tolvaptan	101-110	angiotensinogen	Homo sapiens	130-135	
30801659-4	2019	KEY RESULTS: Tolvaptan suppressed AngII-induced aldosterone production in a dose-dependent manner in H295R cells, whereas neither AVP nor dDAVP in the presence or absence of AngII altered aldosterone production, suggesting the vasopressin V2 receptor was not involved in the inhibitory effect of tolvaptan on aldosterone synthesis.	Tolvaptan	13-22	angiotensinogen	Homo sapiens	34-39	
30801659-5	2019	In addition, tolvaptan inhibited the AngII-induced increase in aldosterone synthase (CYP11B2) protein levels without suppressing CYP11B2 mRNA expression.	Tolvaptan	13-22	angiotensinogen	Homo sapiens	37-42	
30801659-7	2019	In vivo, tolvaptan significantly inhibited AngII-induced increases in serum and adrenal aldosterone levels and CYP11B2 protein levels.	Tolvaptan	9-18	angiotensinogen	Homo sapiens	43-48	
35227907-0	2022	Tolvaptan reduces angiotensin II-induced experimental abdominal aortic aneurysm and dissection.	Tolvaptan	0-9	angiotensinogen	Homo sapiens	18-32